Get the Daily Brief
Latest Biotech News
In vivo CAR T dealmaking accelerates
Johnson & Johnson moved deeper into in vivo CAR T by paying $785 million upfront to collaborate with Sail Biomedicines and taking an option to acquire the company for $2.58 billion. The deal pairs...
Regeneron–Sanofi Dupixent growth and partnership expansion talks
Regeneron reported another strong quarter for Dupixent, driven by label expansions and continued demand across approved indications, with worldwide sales reaching $6 billion for the first time in...
Alnylam ATTR franchise takes earnings-driven hit
Alnylam’s stock slid sharply after the company lowered full-year guidance for its transthyretin amyloidosis franchise, citing normalized Amvuttra demand after a pent-up launch surge. The update...
Novo Nordisk ziltivekimab fails in late-stage heart-inflammation bet
Novo Nordisk disclosed that ziltivekimab failed in a key Phase 3 cardiovascular outcomes study, dealing a setback to an anti-inflammatory approach aimed at linking cardiovascular inflammation to...
FDA advisory panel backs Replimune’s RP-1 for melanoma
Replimune’s RP-1 won support from an FDA advisory committee after the therapy had previously been rejected twice, with panelists concluding the efficacy evidence was evaluable and clinically...
Capricor DMD therapy rejected by FDA adcomm
An FDA advisory committee voted against Capricor’s deramiocel for Duchenne muscular dystrophy cardiomyopathy, capping a meeting marked by dispute over the statistical framing of the underlying...
Oncology testing momentum lifts Guardant and Tempus
Guardant Health posted a sharp revenue increase in the second quarter, driven by oncology testing volume and screening growth, and pointed to the FDA’s June approval of Guardant360 Liquid CDx as a...
Public markets stay open to select biotech IPOs
Apnimed raised $192 million in an upsized IPO to fund its obstructive sleep apnea pill Oxnimbi (AD109), with an FDA decision expected by February 2027. The company increased the offering to 12...
Diagnostics expansion: ABL Diagnostics wins CE-IVD coverage
ABL Diagnostics secured CE-IVD registration for a set of molecular tests covering HIV-1, respiratory pathogens, and viral meningitis panels. The company said its DeepChek Whole Genome HIV-1...
Radiopharma funding: Ratio Therapeutics series C
Ratio Therapeutics raised $70 million for radiopharmaceutical trials as it advances its pipeline through clinical development. The Boston-based company said the Series C came from existing...
FDA and advisory committee outcomes reshape rare-disease cell therapy prospects
Two separate U.S. FDA advisory committee reviews tightened regulatory scrutiny on cell therapies for Duchenne muscular dystrophy, with sharply different next steps for developers. Capricor’s...
In vivo CAR-T dealmaking accelerates as J&J buys options on next-generation platform
Johnson & Johnson expanded its in vivo CAR-T ambitions by striking a collaboration with Sail Biomedicines that includes a large upfront payment and an option to acquire the company. Under the...
Melanoma oncolytic virus therapy gains major FDA-adjacent momentum
Replimune’s RP-1 regained traction with an FDA advisory panel vote after earlier setbacks. Advisers voted 10-3 in favor of the experimental melanoma treatment’s effectiveness, concluding that the...
ATTR franchise weakness rattles Alnylam as Amvuttra outlook cuts hit shares
Alnylam’s stock sold off after the company cut full-year guidance for its ATTR franchise following disappointing Amvuttra growth. Shares dropped as much as 29% after Amvuttra’s second-quarter...
Diagnostics and oncology testing companies raise guidance after strong quarters
Multiple cancer diagnostics firms reported beat-and-raise results, strengthening confidence in demand for genomic testing and liquid biopsy tools. Guardant Health said oncology revenue drove...
MRD and precision diagnostics businesses keep expanding as testing volumes rise
Adaptive Biotechnologies continued to raise its 2026 outlook for minimal residual disease testing as clinical volumes expanded. The company reported Q2 MRD revenue of $66.2 million, up 33% year...
In vivo sequencing platform adoption spreads in Europe via Ultima UG200 certification
BaseClear will adopt Ultima Genomics’ UG200 sequencing platform to support sequencing services for European and global customers. The Netherlands-based genomics services provider is set to become...
Early-stage launch clearance in Australia for in vivo CAR-T candidate CRT-402
Create Medicines received Human Research Ethics Committee approval in Australia to initiate a first-in-human study of CRT-402, its lead in vivo CAR T candidate for autoimmune diseases. The...
Funding and platform expansion: Function Health gets major growth financing from General Catalyst
Function Health secured $450 million in growth financing from General Catalyst’s Customer Value Fund, accelerating its preventive care push. The funding arrives about eight months after the...
Aging biology: mitochondrial–epigenetic crosstalk links to senescent inflammation
Scientists reported a mechanistic link between dysfunctional mitochondria and chronic inflammation in aging that centers on epigenetic activation of inflammatory genes. In a Nature paper titled...